Overview


According to FutureWise analysis the market for exosome technologies in 2023 is US$ 59.13 billion, and is expected to reach US$ 352.92 billion by 2031 at a CAGR of 25.02%.

Exosomes extracted from cow's milk are being used to deliver therapeutic molecules against lung and breast cancer. Exosomes derived from specific sites of the body are promising candidates for anti-cancer vaccines because of their small size, indigenous nature, and ability to cross biological barriers. Therefore, the increase in the number of cancer cases in hospitals directly increases the demand for exosomes for diagnosis and therapy. To successfully implement exosomes in various applications, many technical challenges must be overcome. This is one of the primary barriers to the growth of the exosome market. One of the major hurdles is optimizing the purification process, increasing the homogeneity of exosomes, and developing efficient transfection strategies. Furthermore, a lack of technical information (such as the type of rotor, diameter, volume, and viscosity of the sample) restricts the maximum utilization of exosomes. The cumbersome nature of isolation/purification methods and the inability to distinguish between cancer stages with a limited understanding of the immune system limit the exosome market.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Exosome Technologies Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Exosome Technologies Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Aegle Therapeutics
  • Anjarium Biosciences
  • Aruna Biomedical
  • Carmine Therapeutics
  • Ciloa SAS
  • Codiak BioSciences
  • Organicell
  • OmniSpirant Ltd.
  • Creative Biolabs
  • Evercyte (Beckman Coulter)
  • Direct Biologics
  • Evercyte
  • Evox Therapeutics
  • ExoCan Healthcare Technologies Pvt. Ltd.
  • ExoCoBio
  • ExonanoRNA LLC.
  • Exopharm
  • Exosome Diagnostics, Inc. (BIO-TECHNE CORPORATION)
  • Fujifilm
  • ILIAS Biologics, Inc.
  • Illumina, Inc.
  • Invitrix Therapeutics
  • XOStem, Inc.
  • VivaZome Therapeutics Pty Ltd.
  • Thermo Fisher Scientific, Inc.
  • Novadip Biosciences
  • MDimune Inc.
  • Lonza
  • Kimera Labs
  • QIAGEN
  • Takara Bio, Inc.
  • Tavec Pharma

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Exosome Type

  • Loaded Cargo
    • Peptide
    • siRNA
    • mRNA
    • Protein
    • Chemical
    • Others
  • Non-cargo

By Cell Source

  • HEK293
  • MSCs
  • Platelets
  • Erythrocytes
  • Natural Killer Cells (NKs)
  • Others

By Indication

  • Therapeutics
    • Oncology
    • Neurodegenerative Diseases
    • Cardiovascular Diseases
    • Infectious Diseases
    • Cosmetics
    • Others
  • Diagnostics

By End User

  • Healthcare Providers
  • Pharmaceutical and Biotechnology Companies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Exosome Technologies Market By Exosome Type, By Cell Source, By Indication, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Exosome Technologies Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Exosome Technologies Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Exosome Technologies Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Exosome Technologies Market, By Exosome Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Loaded Cargo
         1.1. Peptide
         1.2. siRNA
         1.3. mRNA
         1.4. Protein
         1.5. Chemical
         1.6. Others
        2. Non-cargo

  • 8.   Exosome Technologies Market, By Cell Source Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. HEK293
        2. MSCs
        3. Platelets
        4. Erythrocytes
        5. Natural Killer Cells (NKs)
        6. Others

  • 9.   Exosome Technologies Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Therapeutics
         1.1. Oncology
         1.2. Neurodegenerative Diseases
         1.3. Cardiovascular Diseases
         1.4. Infectious Diseases
         1.5. Cosmetics
         1.6. Others
        2. Diagnostics

  • 10.   Exosome Technologies Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Healthcare Providers
        2. Pharmaceutical and Biotechnology Companies
        3. Others

  • 11.   North America Exosome Technologies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Exosome Technologies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Exosome Technologies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Exosome Technologies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Aegle Therapeutics
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Anjarium Biosciences
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Aruna Biomedical
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Carmine Therapeutics
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Ciloa SAS
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Codiak BioSciences
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Organicell
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. OmniSpirant Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Creative Biolabs
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Evercyte (Beckman Coulter)
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Direct Biologics
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Evercyte
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Evox Therapeutics
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. ExoCan Healthcare Technologies Pvt. Ltd.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. ExoCoBio
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. ExonanoRNA LLC.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Exopharm
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Exosome Diagnostics, Inc. (BIO-TECHNE CORPORATION)
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Fujifilm
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. ILIAS Biologics, Inc.
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. Illumina, Inc.
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
        22. Invitrix Therapeutics
         22.1. Company Overview
         22.2. Product Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
        23. XOStem, Inc.
         23.1. Company Overview
         23.2. Product Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview
        24. VivaZome Therapeutics Pty Ltd.
         24.1. Company Overview
         24.2. Product Portfolio
         24.3. SWOT Analysis
         24.4. Financial Overview
         24.5. Strategic Overview
        25. Thermo Fisher Scientific, Inc.
         25.1. Company Overview
         25.2. Product Portfolio
         25.3. SWOT Analysis
         25.4. Financial Overview
         25.5. Strategic Overview
        26. Novadip Biosciences
         26.1. Company Overview
         26.2. Product Portfolio
         26.3. SWOT Analysis
         26.4. Financial Overview
         26.5. Strategic Overview
        27. MDimune Inc.
         27.1. Company Overview
         27.2. Product Portfolio
         27.3. SWOT Analysis
         27.4. Financial Overview
         27.5. Strategic Overview
        28. Lonza
         28.1. Company Overview
         28.2. Product Portfolio
         28.3. SWOT Analysis
         28.4. Financial Overview
         28.5. Strategic Overview
        29. Kimera Labs
         29.1. Company Overview
         29.2. Product Portfolio
         29.3. SWOT Analysis
         29.4. Financial Overview
         29.5. Strategic Overview
        30. QIAGEN
         30.1. Company Overview
         30.2. Product Portfolio
         30.3. SWOT Analysis
         30.4. Financial Overview
         30.5. Strategic Overview
        31. Takara Bio, Inc.
         31.1. Company Overview
         31.2. Product Portfolio
         31.3. SWOT Analysis
         31.4. Financial Overview
         31.5. Strategic Overview
        32. Tavec Pharma
         32.1. Company Overview
         32.2. Product Portfolio
         32.3. SWOT Analysis
         32.4. Financial Overview
         32.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients